07:00 , May 19, 2014 |  BioCentury  |  Finance

Giving Chase in AD

Giving Chase in AD While the Alzheimer's disease space is littered with failed disease-modifying compounds, Chase Pharmaceuticals Corp. is taking a different tack. The company is combining undisclosed molecules with marketed AD drugs to improve...
02:05 , May 13, 2014 |  BC Extra  |  Financial News

Chase secures $21 million in series B

Alzheimer's disease play Chase Pharmaceuticals Corp. (Washington, D.C.) raised an undisclosed amount in a tranched $21 million series B round led by new investor New Rhein Healthcare Investors. New investors Edmond de Rothschild Investment Partners...
07:00 , Jun 9, 2008 |  BioCentury  |  Strategy

Adding shots on goal

A long-standing critique of German biotech companies is that they are too small and rely too much on a single lead program. Two companies last week took steps to change that equation. 4SC AG for...